PolyPid

Company Overview

Snapshot

Founded in February 2008, PolyPid operates with 51–200 employees. The company has raised a total of $239.24M across 15 funding rounds from 8 investors. In January 2024, PolyPid secured a private placement from Rosalind Advisors and DAFNA Capital Management.

Business overview

PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology enables the precise, controlled, and prolonged delivery of active pharmaceutical ingredients, ranging from days to months. The company's lead product candidate, D-PLEX100, is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. Additionally, its OncoPLEX is in preclinical testing for treating solid tumors, starting with glioblastomas. PolyPid operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, serving the pharmaceutical industry in Europe and the United States.

Strategic signal

In October 2024, PolyPid announced the publication in the International Journal of Surgery highlighting the results of its Phase 3 SHIELD I trial for D-PLEX₁₀₀ in preventing surgical site infections in abdominal colorectal surgery. This publication provides significant clinical validation for its lead product, reinforcing the potential of its PLEX technology platform and signaling strong progress towards commercialization to investors.

Company Intelligence Q&A

What was a key financial event for PolyPid in January 2024?

In January 2024, PolyPid announced a private placement for $16 million in gross proceeds, with participation from Rosalind Advisors.

When did PolyPid go public?

PolyPid went public on NASDAQ in June 2020.

What was the outcome of the Phase 3 SHIELD I trial for D-PLEX₁₀₀?

In October 2024, PolyPid announced the publication of results from its Phase 3 SHIELD I trial of D-PLEX₁₀₀ for the prevention of surgical site infections in abdominal colorectal surgery in the International Journal of Surgery.

What is the latest update on PolyPid's D-PLEX₁₀₀ clinical development?

In October 2024, PolyPid announced the last patient was in for the planned unblinded interim analysis in the ongoing SHIELD II Phase 3 Trial evaluating D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections.

What was a significant operational milestone for PolyPid in September 2023?

In September 2023, PolyPid announced the successful completion of a Commercial Good Manufacturing Practice (GMP) Audit by the Israeli Ministry of Health.